FDA ACTIONS

Dasatinib use may increase risk of PAH

Dasatinib (Sprycel, Bristol-Myers Squibb) may increase the risk of PAH, a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs, announced a recent FDA Drug Safety Communication issued to healthcare professionals. » More

FDA approves Combivent Respimat Inhalation Spray for patients with COPD

FDA has approved ipratropium bromide and albuterol (Combivent Respimat Inhalation Spray, Boehringer Ingelheim) for patients with COPD who use a regular aerosol bronchodilator and who require a second bronchodilator. » More

FDA approves sitagliptin and simvastatin combination therapy

FDA has approved sitagliptin and simvastatin (Juvisync, MSD International GmbH Clonmel), a fixed-dose combination prescription medication, for use by adults who have type 2 diabetes and high cholesterol levels. » More

FDA approves tadalafil to treat benign prostatic hyperplasia and ED

FDA recently approved tadalafil (Cialis, Eli Lilly) tablets for once-daily use for the treatment of 3 indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions. » More

TECHNOLOGY

Diabetes Navigator showcases type 2 diabetes resources online

The AACE and Takeda Pharmaceuticals North America Inc. have partnered to launch the Diabetes Navigator, a collection of type 2 diabetes information available online for patients and caregivers. » More

New compact tablet counter is fast and accurate

Kirby Lester’s compact new KL1 tablet counter offers a compelling option for space-constrained pharmacies. » More

Voices

•	Anticoagulation update
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.